Citigroup
TCRT icon

Citigroup’s Alaunos Therapeutics TCRT Stock Holding History

Citigroup’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-328
Closed -$124K – 7329
2020
Q4 		$124K Hold
328
– – ﹤0.01% 5367
2020
Q3 		$124K Hold
328
– – ﹤0.01% 4954
2020
Q2 		$161K Sell
328
-1
-0.3% -$446 ﹤0.01% 5187
2020
Q1 		$121K Sell
329
-104
-24% -$53.8K ﹤0.01% 5191
2019
Q4 		$306K Sell
433
-292
-40% -$201K ﹤0.01% 4834
2019
Q3 		$465K Buy
725
+324
+81% +$257K ﹤0.01% 4412
2019
Q2 		$350K Sell
401
-354
-47% -$243K ﹤0.01% 4786
2019
Q1 		$436K Buy
755
+519
+220% +$217K ﹤0.01% 4331
2018
Q4 		$66K Buy
236
+187
+382% +$73.9K ﹤0.01% 6008
2018
Q3 		$24K Sell
49
-25
-34% -$10.7K ﹤0.01% 7003
2018
Q2 		$34K Sell
74
-55
-43% -$34.9K ﹤0.01% 6589
2018
Q1 		$76K Sell
129
-290
-69% -$181K ﹤0.01% 5847
2017
Q4 		$260K Buy
419
+88
+27% +$63.2K ﹤0.01% 4795
2017
Q3 		$305K Sell
331
-139
-30% -$123K ﹤0.01% 4607
2017
Q2 		$439K Buy
470
+182
+63% +$178K ﹤0.01% 4108
2017
Q1 		$274K Sell
288
-124
-30% -$115K ﹤0.01% 4391
2016
Q4 		$331K Buy
412
+56
+16% +$50.5K ﹤0.01% 4808
2016
Q3 		$301K Sell
356
-171
-32% -$137K ﹤0.01% 4349
2016
Q2 		$434K Sell
527
-120
-19% -$131K ﹤0.01% 3821
2016
Q1 		$720K Buy
647
+78
+14% +$79.8K ﹤0.01% 3726
2015
Q4 		$710K Buy
569
+58
+11% +$95.9K ﹤0.01% 3505
2015
Q3 		$691K Buy
511
+169
+49% +$279K ﹤0.01% 3440
2015
Q2 		$616K Buy
342
+195
+133% +$303K ﹤0.01% 3516
2015
Q1 		$237K Buy
+147
New +$218K ﹤0.01% 4376

Other funds holding TCRT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup's TCRT Position: Q2 2026 in Review

Citigroup sold out of Alaunos Therapeutics (TCRT) in Q2 2026, closing a stake of 1 share — an estimated $3 sold.

Citigroup first reported a position in TCRT in Q2 2013 and held it in 45 quarters. The position peaked at $3.04M in Q1 2021. 29 funds tracked by Wall St. Rank hold TCRT as of Q2 2026.

  • Citigroup reported no remaining Alaunos Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 1 Alaunos Therapeutics share in Q2 2026, an estimated $3.
  • Citigroup first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 45 quarters.
  • Citigroup's Alaunos Therapeutics position peaked at $3.04M in Q1 2021.
  • 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.